Evidence map›Paper›PMID 37057870›Full record

ArticlePathology international2023

Pattern of MUC6 expression across 119 different tumor types: A tissue microarray study on 15 412 tumors.

Sebastian Dwertmann Rico, Sebastian J A Schliesser, Natalia Gorbokon, David Dum, Anne Menz, Franziska Büscheck, Andrea Hinsch, Maximilian Lennartz, Clara von Bargen, Ahmed A Bawahab and 16 more

Open access · hybridAbstract read
In one paragraph

Article in Pathology international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Multiple roles and mechanisms of MUC6 in cancer (Review).International journal of molecular medicine · 2025
    Review
  3. Comprehensive histopathological analysis of gastric cancer in European and Latin America populations reveals differences in PDL1, HER2, p53 and MUC6 expression.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025
    Article
  4. Review
  5. AmiCa: Atlas of miRNA-gene correlations in cancer.Computational and structural biotechnology journal · 2024
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 1 institution in 2 countries.

Sebastian Dwertmann RicoInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Sebastian J A SchliesserInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Natalia GorbokonInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
David DumInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Anne MenzInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Franziska BüscheckInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Andrea HinschInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Maximilian LennartzInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Clara von BargenInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Ahmed A BawahabInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Andreas M LuebkeInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Claudia Hube-MaggInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Christoph FrauneInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Patrick LebokInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Till S ClauditzInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Frank JacobsenInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Guido SauterInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Ria UhligInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Stefan SteurerInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Sarah MinnerInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Andreas H MarxInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Ronald SimonInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID http://orcid.org/0000-0003-0158-4258
Eike BurandtInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Doris HoeflmayerInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Till KrechInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Christian BernreutherInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Universität Hamburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mucin 6 (MUC6) is a secreted gel-forming mucin covering the surfaces of gastrointestinal and other tissues. Published work demonstrates that MUC6 can also be expressed in several cancer types and can aid in the distinction of different tumor entities. To systematically analyze MUC6 expression in normal and cancerous tissues, a tissue microarray containing 15 412 samples from 119 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry. At least a weak MUC6 positivity was seen in 50 of 119 (42%) tumor entities. Thirty-three tumor entities included tumors with strong positivity. MUC6 immunostaining was most frequent in mucinous carcinomas of the breast (44%), adenocarcinomas of the stomach (30%-40%) and esophagus (35%), and neuroendocrine carcinomas of the colon. Strong MUC6 staining was linked to advanced pT stage (p = 0.0464), defective mismatch repair status and right-sided tumor location (p < 0.0001 each) in colorectal cancer, as well as to high tumor grade (p = 0.0291), nodal metastasis (p = 0.0485), erb-b2 receptor tyrosine kinase 2 positivity (p < 0.0001) and negative estrogen receptor (p = 0.0332)/progesterone receptor (p = 0.0257) status in breast carcinomas of no special type. The broad range of tumor types with MUC6 expression limits the utility of MUC6 immunohistochemistry for the distinction of different tumor types.

Indexed as

AdenocarcinomaBreast NeoplasmsBiomarkers, TumorFemaleHumansImmunohistochemistryMucin-6MucinsBiomarkers, TumorMUC6 protein, humanMucin-6Mucinsdiagnostichuman cancerimmunohistochemistryMUC6tissue microarray

Identifiers

PMID37057870
PMCPMC11551819
OpenAlexW4365479553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.